Provided by Tiger Fintech (Singapore) Pte. Ltd.

Carisma Therapeutics

0.2152
-0.0027-1.24%
Post-market: 0.22500.0098+4.55%18:30 EDT
Volume:281.67K
Turnover:61.97K
Market Cap:8.99M
PE:-0.15
High:0.2285
Open:0.2179
Low:0.2058
Close:0.2179
Loading ...

Company Profile

Company Name:
Carisma Therapeutics
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
46
Office Location:
3675 Market Street,Suite 200,Philadelphia,Pennsylvania,United States
Zip Code:
19104
Fax:
- -
Introduction:
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Directors

Name
Position
Thomas R. Cannell
President and Chief Executive Officer and Director
Jay S. Duker
Chair of the Board
Carrie L. Bourdow
Director
Jane V. Henderson
Director
Jason A. Keyes
Director

Shareholders

Name
Position
Thomas R. Cannell
President and Chief Executive Officer and Director
Monica Forbes
Chief Financial Officer and Treasurer
Glen MacDonald
Chief Technology Officer
Mark R. Sullivan
General Counsel & Corporate Secretary